Dr Luke Wee
November 19, 2026

Founders Keep Choosing the Wrong Doctors

Why the most luxurious medicine may be the medicine you do not use
Found this valuable? Share it forward.

A founder tells me he is unhappy with his doctor. Nothing has been missed — no diagnostic disaster, no medication error, no failure anyone could point to. His blood pressure has drifted upward, his cholesterol is not quite where it should be, he sleeps badly, and a collection of minor symptoms has become more interesting at 45 than it was at 35. His doctor reviewed the results, discussed the obvious things, suggested a few changes, and proposed repeating some measurements in a few months.

"He didn't really do anything."

I have heard versions of this sentence often enough to become interested in it, and the founder is not being unreasonable. In most of his working life, unanswered questions are actionable. If information is missing, someone can obtain it; if expertise is required, someone can be found; if a decision can be brought forward, there is usually an advantage in doing so. He has spent a career learning that agency matters, and he has generally been right.

He also has legitimate grounds for distrusting inaction in medicine specifically. For many patients, "let's wait and see" is not a carefully defended clinical position but shorthand for a system that cannot fit them in, a referral that will take months, or a problem nobody quite owns. Everyone knows someone whose symptoms were watched into a late diagnosis. Suspicion of passivity has a real basis.

So the mistake is not impatience, and it is not a failure of judgement. It is that he is applying an excellent rule in the one domain where its central premise quietly fails.

In much of business, obtaining more information is relatively cheap, and if it proves irrelevant it can usually be ignored. Medicine is unusual because information can create obligations. A test produces a finding, the finding demands follow-up, the follow-up produces a procedure, the procedure produces a complication, and none of the steps were unreasonable when taken individually. Scan enough healthy people and something will eventually appear; measure enough biomarkers and some will sit outside a reference range; ask enough thoughtful specialists and eventually two of them will disagree. Availability of action and quality of action are different things, and they come apart most sharply for the patients with the most access.

The Wrong Kind of Good Doctor

For most patients, many branches of that decision tree are theoretical. For a sufficiently resourceful patient, they are all real. The cardiologist can be seen tomorrow, the MRI can happen this week, a second opinion can be arranged, someone knows the professor, another panel costs relatively little. If one doctor advises waiting, another can usually be found who is willing to investigate. Which is where successful people can make a selection error when choosing doctors.

They ask for someone proactive — comprehensive, responsive, data-driven, at the frontier, someone who will investigate properly and not dismiss a concern just because the standard bloods are normal. None of these are unreasonable qualities to want; I would want several of them myself, and the doctors who possess them are often excellent.

The founder is not choosing poor clinical quality. He is choosing for the characteristics that reliably signal quality everywhere else in his life: responsiveness, depth of resources, decisiveness, the ability to mobilise expertise quickly.

Medicine needs all of these. But selected together, and in a setting where every option is purchasable, they select for a medicine that does things — and if you are wealthy enough, medicine can do an extraordinary number of things to you.

I should say that I am not describing this from outside it. I have wanted the scan. I have caught myself wanting a number explained today rather than in three months, and knowing the literature on incidental findings does not reliably stop me. This is not a founder pathology. It is what capability does to anyone who has it, and it happens to be most available to the people best equipped to buy it.

Here is the part that took me longest to see clearly: restraint in medicine is a resource before it is a virtue, and most patients cannot safely afford it.

Scarcity Compresses the Decision Horizon

Waiting is easy when you know you can come back. Watching a symptom is safer when another appointment exists next week. Repeating a blood test in three months is reasonable when you have the time, money and continuity to make sure the test actually gets repeated. Declining a referral is easier when you know one can be arranged quickly if the picture changes. Many patients cannot assume any of this. They get one appointment and cannot be certain of the next. Another day away from work has consequences; a specialist may take months; the next doctor may never have met them. Scarcity compresses the decision horizon: more has to be settled today because tomorrow cannot be assumed.

Photo by Ante Hamersmit on Unsplash

At the other hand, the well-resourced patient can afford another appointment, another test and another opinion. More importantly, he can afford not to have them yet. This may be the least appreciated privilege of high-resource medicine: it can buy time, and time itself can be diagnostic. An ambiguous symptom declares itself over six weeks. A mildly abnormal result normalises. A small radiological finding remains unchanged. A difficult decision becomes easier because nothing happens. This is not neglect. It is optionality.

When Access Reduces Optionality

And founders, of all people, understand optionality. They do not deploy every available dollar simply because the money exists. They preserve runway, stage commitments, keep decisions reversible while uncertainty is high, and they know an option can carry considerable value even when it is never exercised. A scan is an option. A specialist appointment is an option. A second opinion is an option. The existence of the option does not oblige you to spend it. Which makes the pattern I see less a failure of discipline than a feature of the market around him. The patient with the greatest capacity to wait is also the patient offered the greatest number of alternatives to waiting. The temptation is not that he cannot tolerate uncertainty; it is that he can do something about almost every uncertainty, and each of those things is available today, from someone willing to provide it.

The Market Rewards More

Executive healthcare is built to encourage the exception, because speed and abundance are visible. There is an impressive machine for the scan that was ordered, a report from the specialist who was consulted, a dashboard full of biomarkers. There is no machine for the scan that was not needed, no letter from the referral that did not happen, no graph showing the incidentaloma that was never found or the anxiety that was never generated.

The commercial incentives are therefore peculiar: the patients most able to afford less medicine are also the patients from whom healthcare has the greatest incentive to provide more of it. Add status to the room, and the drift becomes easier still. Status changes rooms, and doctors are not immune. A prominent patient's request becomes slightly easier to grant. A probably unnecessary investigation feels harmless because he can afford it. A referral is easier than a disagreement. The patient leaves feeling taken seriously, the doctor leaves feeling responsive, and nothing obviously bad has happened — which is precisely why the dynamic is so easy to miss.

The worst doctor for a powerful person may be the doctor who is easily impressed by powerful people.

So a good private doctor cannot merely remove friction from healthcare. Sometimes the doctor has to be the friction. Not administrative friction — there is nothing noble about unanswered phones, three-month waiting lists, or making someone fax a referral somewhere in 2026 — but clinical friction: the pause between wanting a test and ordering it, the question of what we would actually do differently if the result were abnormal, the willingness to let a question stay unresolved for another three months, the refusal to convert every available capability into an indication to use it.

In practice, this is less about refusing patients than asking better questions. Why do you want the hormones higher? What would ruling out every cancer actually require? How certain can medicine make you about a heart attack?

Sometimes the answer is still yes: scan it, refer, pursue the diagnosis. The point is having a doctor who can distinguish an available action from a useful one, and who can still say no when yes would be easier and better paid.

Photo by Aaron Ang on Unsplash

The Luxury of Restraint

There is a hierarchy of medical luxury, and most executive healthcare stops at the second rung. The first luxury is speed: you do not wait six weeks; the scan happens tomorrow. The second is abundance: more expertise, more technology, more choices than most patients could obtain in a lifetime. The third is restraint — enough access that you do not need to demonstrate it by using it, enough continuity that a problem can remain unresolved without being abandoned, enough specialist availability that deferring a referral does not mean losing the opportunity, enough trust that "let's leave this alone" does not sound like "I don't care." Doing less is only luxurious when doing more remains readily available.

Which is why access changes the meaning of restraint entirely. For a patient with poor access, waiting can mean losing the chance to act. For a patient with abundant access, waiting preserves the chance to act later, with better information. From the outside the behaviour is identical — nothing happens today — but clinically these are very different forms of nothing.

When Nothing Is the Treatment

Which brings me back to the founder. It is possible his doctor is complacent; that happens, and he should satisfy himself it hasn't, because "wait and see" can conceal poor medicine just as easily as unnecessary investigation can masquerade as thoroughness. But there is another possibility: that he was offered something executive healthcare is surprisingly bad at selling — a considered decision not to act yet, made by someone willing to stay responsible while the uncertainty persists. There is no way to recognise it, because it arrived looking exactly like nothing.

Founders are unusually good at creating optionality. The rare doctor is the one who can credibly tell them not to spend it all.

Dr Luke Wee is a private physician working across Australia and New Zealand. He writes about medicine, judgement and the things good doctors sometimes choose not to do.

First published in The Longer Consultation on LinkedIn, 15 September 2026. Cover photograph: Auroom Wellness on Unsplash.

Related reading